SOURCE: Medistem Laboratories

May 06, 2008 07:05 ET

Medistem to Present on Its Progress in Its Menstrual Derived Stem Cell Program (ERC)

BioFinance 2008 Presentation to Highlight ERC Clinical Path

SAN DIEGO, CA and SCOTTSDALE, AZ--(Marketwire - May 6, 2008) - Medistem Laboratories, Inc. (OTCBB: MDSM), a biotechnology company dedicated to commercialization of its novel, universal donor, stem cell population, the Endometrial Regenerative Cell (ERC), is pleased to announce its upcoming presentation at the BioFinance 2008 meeting.

Medistem will review its recent progress in the development of an "off the shelf" product for the treatment of critical limb ischemia, an advanced form of peripheral vascular disease. The company will also provide an overview of its current scientific and regulatory strategy, as well as its ongoing research efforts.

Thomas Ichim, CEO of Medistem, commented, "Recent animal study data conducted by one of our collaborators suggests ERC are potent stimulators of new blood vessel production, a process called angiogenesis." He continued, "By leveraging the natural ability of these cells to make new blood vessels, along with their potent ability to produce therapeutic growth factors, we feel these cells are a potentially ideal product to use in the treatment critical limb ischemia, a condition that causes 150,000 amputations per year in the USA."

Medistem has previously published that its ERC stem cell source is capable of differentiating into 9 different tissues and possesses a unique functional and phenotypic profile as compared to other adult stem cells. A free copy of the publication may be obtained at http://www.medisteminc.com/publications.html

Medistem's Thomas Ichim will present on Wednesday, May 7th, at 4 PM EDT in the Trinity I room of the Toronto Marriott Eaton Centre.

About Medistem Laboratories

Medistem Laboratories is a biotechnology company founded to develop and commercialize technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell derived from the menstrual blood that possesses the ability to differentiate into nine tissue types, produce large quantities of growth factors, and a large proliferative capacity. Medistem is leveraging relationships and collaborative efforts with international institutes to accelerate clinical entry of its ERC products.

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies and receive associated licensing fees; plans relating to the company's products and services; and assumptions relating to the foregoing.

Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.

Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: the company's ability to anticipate future license fees, technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs.

These factors are discussed in greater detail in the company's quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission.

Contact Information